InsiderClue
Insiders · Profile

Behbahani Ali

Director at CRISPR Therapeutics · Director at SpyGlass Pharma · 10% owner at MBX Biosciences · and 6 more. Filing since 9 May 2019. CIK 0001613867

CRSP CRISPR Therapeutics AG Director · 1 trade SGP SpyGlass Pharma, Inc. Director · 1 trade MBX MBX Biosciences, Inc. 10% owner · 1 trade SVRA Savara Inc 10% owner · 1 trade BDTX Black Diamond Therapeutics, Inc. Director · 2 trades TRVI Trevi Therapeutics, Inc. 10% owner · 4 trades GLUE Monte Rosa Therapeutics, Inc. Director · 1 trade MRKR Marker Therapeutics, Inc. 10% owner · 1 trade MIRM Mirum Pharmaceuticals, Inc. 10% owner · 1 trade
Company
Date
Role
Action
Shares
Amount
Of holding
CRSP CRISPR Therapeutics AG
17 Sep 2026
Director
Sold at will
13,679
$780.94K
45.1%
SGP SpyGlass Pharma, Inc.
9 Feb 2026
Director
Bought
937,500
$15.00M
18.4%
MBX MBX Biosciences, Inc.
16 Sep 2024
10% owner
Bought
500,000
$8.00M
16.1%
SVRA Savara Inc
17 Jul 2023
10% owner
Bought
333,333
$1,000.00K
1.4%
BDTX Black Diamond Therapeutics, Inc.
5 Jul 2023
Director
Bought
1,000,000
$5.00M
29.0%
TRVI Trevi Therapeutics, Inc.
11 Apr 2022
10% owner
Bought
3,580,526
$6.80M
52.3%
TRVI Trevi Therapeutics, Inc.
18 Oct 2021
10% owner
Bought
1,851,852
no price
31.2%
GLUE Monte Rosa Therapeutics, Inc.
28 Jun 2021
Director
Bought
1,050,000
$19.95M
15.8%
MRKR Marker Therapeutics, Inc.
16 Mar 2021
10% owner
Bought
5,714,285
$10.00M
114%
TRVI Trevi Therapeutics, Inc.
3 Apr 2020
10% owner
Sold, plan not stated
564
$1.50K
0.0%
BDTX Black Diamond Therapeutics, Inc.
3 Feb 2020
Director
Bought
800,000
$15.20M
30.2%
MIRM Mirum Pharmaceuticals, Inc.
22 Jul 2019
10% owner
Bought
450,000
$6.75M
12.0%
TRVI Trevi Therapeutics, Inc.
9 May 2019
10% owner
Bought
2,500,000
$25.00M
129%
13 decisions on file.